Login / Signup

Beta Blockers Improve Prognosis When Used Early in Patients with Cardiogenic Shock: An Analysis of the FRENSHOCK Multicenter Prospective Registry.

Laura Sofia CardelliMiloud CherbiFabien HuetGuillaume SchurtzEric Bonnefoy-CudrazEdouard GerbaudLaurent BonelloGuillaume LeurentEtienne PuymiratGianni CasellaClément DelmasFrancois Roubille
Published in: Pharmaceuticals (Basel, Switzerland) (2023)
BBs are drugs of first choice in patients with HF and should also be considered early in patients with CS. In contrast, the discontinuation of BB therapy resulted in increased 1-month all-cause mortality and a trend toward increased 1-year all-cause mortality.
Keyphrases
  • magnetic resonance
  • growth factor
  • stem cells
  • computed tomography
  • magnetic resonance imaging
  • cell therapy
  • double blind
  • contrast enhanced
  • recombinant human